The Telix Pharmaceuticals Ltd (ASX: TLX) share price is off to the races today.
Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $14.36. In earlier trade, shares leapt to $16.89 each, up 17.6%. At the time of writing, shares are changing hands for $16.63 apiece, up 15.8%.
For some context, the ASX 200 is up 0.9% at this same time.
Here's what's grabbing investor interest on Wednesday.
Image source: Getty Images
Telix share price rockets on revenue growth
After market close yesterday, Telix released its third-quarter update (Q3 2025), covering the three months to 30 September.
And, as you can tell by the surging Telix share price today, there was a lot to like about the company's performance.
Among the highlights, the company reported a 53% year-on-year increase in unaudited revenue to US$206 million.
The third quarter saw Telix receive full reimbursement for its Gozellix product from the US Centers for Medicare and Medicaid Services.
And the company said it launched its Illuccix product in 19 European Union markets and the United Kingdom, with a commercial launch having commenced in the UK, Germany, France, Finland, Sweden, Norway, and Denmark.
In light of the strong quarterly performance which is likely offering an added boost to the Telix share price today, the ASX 200 healthcare company raised its full calendar revenue guidance to the range of US$800 to US$820 million, up from prior guidance of US$770 to US$800 million.
A word from the CEO
Commenting on the quarterly results sending the Telix share price surging today, CEO Christian Behrenbruch said, "We believe this is a solid result, particularly in light of the reimbursement dynamics during the quarter."
He said this sees the company kicking off the fourth quarter "in a position of strength".
Behrenbruch said Telix's outlook is "supported by a growing customer base, two FDA-approved PSMA imaging agents and CMS reimbursement for Gozellix effective from 1 October in the US".
He concluded:
This differentiated two-product strategy enables us to expand market share across all customer segments, with Gozellix enhancing our production flexibility and providing customer choice based on patient reimbursement pathways.
With today's intraday boost factored in, the Telix share price remains down 24% since this time last year.
And, according to consensus analyst recommendations on CommSec, the ASX 200 stock is a "strong buy", with 12 of the 15 analysts recommending Telix as a strong buy and three as a moderate buy. There are no hold or sell recommendations on the stock.
